Ex-Jazz Saks elected to Depomed board
This article was originally published in Scrip
Executive Summary
Speciality pharma company Depomed has appointed Jazz Pharmaceuticals' former co-founder Dr Samuel Saks to the company's board of directors. Dr Saks served as Jazz's CEO from 2003-2009.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.